Cargando…
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
PI3K-δ and PI3K-γ are critical regulators of T-cell differentiation, senescence, and metabolism. PI3K-δ and PI3K-γ signaling can contribute to T-cell inhibition via intrinsic mechanisms and regulation of suppressor cell populations, including regulatory T-cells and myeloid derived suppressor cells i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427697/ https://www.ncbi.nlm.nih.gov/pubmed/34512641 http://dx.doi.org/10.3389/fimmu.2021.718621 |
_version_ | 1783750230072623104 |
---|---|
author | Chandrasekaran, Sanjay Funk, Christopher Ronald Kleber, Troy Paulos, Chrystal M. Shanmugam, Mala Waller, Edmund K. |
author_facet | Chandrasekaran, Sanjay Funk, Christopher Ronald Kleber, Troy Paulos, Chrystal M. Shanmugam, Mala Waller, Edmund K. |
author_sort | Chandrasekaran, Sanjay |
collection | PubMed |
description | PI3K-δ and PI3K-γ are critical regulators of T-cell differentiation, senescence, and metabolism. PI3K-δ and PI3K-γ signaling can contribute to T-cell inhibition via intrinsic mechanisms and regulation of suppressor cell populations, including regulatory T-cells and myeloid derived suppressor cells in the tumor. We examine an exciting new role for using selective inhibitors of the PI3K δ- and γ-isoforms as modulators of T-cell phenotype and function in immunotherapy. Herein we review the current literature on the implications of PI3K-δ and -γ inhibition in T-cell biology, discuss existing challenges in adoptive T-cell therapies and checkpoint blockade inhibitors, and highlight ongoing efforts and future directions to incorporate PI3K-δ and PI3K-γ as synergistic T-cell modulators in immunotherapy. |
format | Online Article Text |
id | pubmed-8427697 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84276972021-09-10 Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ Chandrasekaran, Sanjay Funk, Christopher Ronald Kleber, Troy Paulos, Chrystal M. Shanmugam, Mala Waller, Edmund K. Front Immunol Immunology PI3K-δ and PI3K-γ are critical regulators of T-cell differentiation, senescence, and metabolism. PI3K-δ and PI3K-γ signaling can contribute to T-cell inhibition via intrinsic mechanisms and regulation of suppressor cell populations, including regulatory T-cells and myeloid derived suppressor cells in the tumor. We examine an exciting new role for using selective inhibitors of the PI3K δ- and γ-isoforms as modulators of T-cell phenotype and function in immunotherapy. Herein we review the current literature on the implications of PI3K-δ and -γ inhibition in T-cell biology, discuss existing challenges in adoptive T-cell therapies and checkpoint blockade inhibitors, and highlight ongoing efforts and future directions to incorporate PI3K-δ and PI3K-γ as synergistic T-cell modulators in immunotherapy. Frontiers Media S.A. 2021-08-26 /pmc/articles/PMC8427697/ /pubmed/34512641 http://dx.doi.org/10.3389/fimmu.2021.718621 Text en Copyright © 2021 Chandrasekaran, Funk, Kleber, Paulos, Shanmugam and Waller https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Chandrasekaran, Sanjay Funk, Christopher Ronald Kleber, Troy Paulos, Chrystal M. Shanmugam, Mala Waller, Edmund K. Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ |
title | Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ |
title_full | Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ |
title_fullStr | Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ |
title_full_unstemmed | Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ |
title_short | Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ |
title_sort | strategies to overcome failures in t-cell immunotherapies by targeting pi3k-δ and –γ |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427697/ https://www.ncbi.nlm.nih.gov/pubmed/34512641 http://dx.doi.org/10.3389/fimmu.2021.718621 |
work_keys_str_mv | AT chandrasekaransanjay strategiestoovercomefailuresintcellimmunotherapiesbytargetingpi3kdandg AT funkchristopherronald strategiestoovercomefailuresintcellimmunotherapiesbytargetingpi3kdandg AT klebertroy strategiestoovercomefailuresintcellimmunotherapiesbytargetingpi3kdandg AT pauloschrystalm strategiestoovercomefailuresintcellimmunotherapiesbytargetingpi3kdandg AT shanmugammala strategiestoovercomefailuresintcellimmunotherapiesbytargetingpi3kdandg AT walleredmundk strategiestoovercomefailuresintcellimmunotherapiesbytargetingpi3kdandg |